Lyvispah (Baclofen) Patent Expiration, LOE Window & CMS Spending

Lyvispah (Baclofen) by Strides International Ag: FDA Orange Book LOE 2041-09-29, 19 AB generics, $369K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorStrides International Ag
FDA Application & PathwayN215422 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-09-29
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$369K
2024 Medicare Part D Spend$163K
2024 Medicaid Spend$206K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel